1-4 of 4
Ralph B. Arlinghaus, Ph.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Enhanced Jak2 Activation Correlates with β Chain Expression Leading to Phosphorylation of Tyrosine 177 of Bcr-Abl.

Wenjing Tao, Ph.D., Ajoy K. Samanta, Ph.D., Waldemar Priebe, Ph.D., Ralph B. Arlinghaus, Ph.D.
Journal: Blood
Blood (2009) 114 (22): 2170.
https://doi.org/10.1182/blood.V114.22.2170.2170
Published: 2009
Journal Articles

Jak2: A Potential Therapeutic Target for Chronic Myelogenous Leukemia (CML).

Ajoy K. Samanta, PhD, Hui Lin, M.D., Tong Sun, M.S., Hagop Kantarjian, M.D., Ralph B. Arlinghaus, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 2121.
https://doi.org/10.1182/blood.V108.11.2121.2121
Published: 2006
Journal Articles

Vaccination with Leukemia Cells Expressing Cell-Surface-Associated GM-CSF Blocks Leukemia Induction in Immunocompetent Mice.

Xiaoyang Ling, Ph.D, Yan Wang, M.D., Ralph B. Arlinghaus, Ph.D.
Journal: Blood
Blood (2004) 104 (11): 2531.
https://doi.org/10.1182/blood.V104.11.2531.2531
Published: 2004
Journal Articles

AMN107, Novel Aminopyrimidine Inhibitor of Bcr-Abl, Is Significantly More Potent Than Imatinib Mesylate Against Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells.

Mirna Golemovic, M.S., Miloslav Beran, M.D., Ph.D., Francis Giles, M.D., Taghi Manshouri, M.S.C., Deborah Thomas, M.D., Jorge Cortes, M.D., Paul Manley, M.D., Leila Alland, M.D., Patricia Rae, B.S.C., Margaret Dugan, M.D., Zeev Estrov, M.D., Ralph B. Arlinghaus, Ph.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Ph.D.
Journal: Blood
Blood (2004) 104 (11): 2737.
https://doi.org/10.1182/blood.V104.11.2737.2737
Published: 2004